Document:

ex10_1.htm

Exhibit 10.1

 

 

March 14, 2016

Jason Richardson

Dear Jason:

 

I am pleased to offer you the position of VP, Controller reporting directly to me. I am confident that this role will allow you to continue to make a major contribution to Hill-Rom and help us deliver on our mission: Every day, around the world, we enhance outcomes for our patients and their caregivers. With your help, together we can continue to make a real difference in healthcare, and in doing so, create sustainable shareholder value.

 

The specifics of the offer are as follows:

  

	
  

	
1.

	
An effective date of March 14, 2016.

	
  

	
2.

	
Your annual base salary will increase to $240,000 effective with this promotion.

	
  

	
3.

	
You will continue to be eligible for the Short-Term Incentive Compensation (STIC) program.  Your target incentive will increase to 40% of base salary effective with this promotion.  For fiscal year 2016, your STIC payout will be pro-rated at each level based on time in position.

	
  

	
4.

	
You will continue to be eligible for the Long Term Incentive (LTI) program.  Your target incentive will be 40% of base salary. Grants are awarded annually and approved in November by the Company’s Board of Directors.

 

	
  

	
5.

	
You will receive a one-time award of shares of Restricted Stock Units (RSUs) of Hill-Rom Holdings, Inc. with a value of $50,000 in recognition of your promotion.  The number of shares will be determined based on the stock price on the effective date of your promotion.  This award will fully vest on the day following the third anniversary of the effective date of the award.  Shortly, you will be provided with a Hill-Rom Holdings, Inc. stock award agreement providing the terms and additional details regarding your award. 

 

	
  

	
6.

	
Your PTO will not change as eligibility is based on years of service.

 

	
  

	
7.

	
Should your employment be terminated by the Company without cause, you will receive severance pay equivalent to six months’ base salary.

Jason, I am excited to have you in this role and I look forward to the contributions you will continue to make to Hill-Rom. If you have any questions, please give me a call.

Sincerely,

/s/ Steve Strobel

 

SVP Chief Financial Officer

 

	

/s/ Jason Richardson

	 	

3/14/16

	 
	

Acceptance

	 	

DateExhibit 10.23

 

SERVICES AGREEMENT

 

THIS SERVICES AGREEMENT (this “Agreement”)
is entered into effective as of February 1, 2016, by and between Interleukin Genetics, Inc., a Delaware corporation
with an address of 135 Beaver Street, Waltham, MA 02452 (“INTERLEUKIN”), and Metagenics, Inc.,
a Delaware corporation with an address of 25 Enterprise, Suite 200, Aliso Viejo, CA 92656 (“METAGENICS”).

 

Each of INTERLEUKIN and METAGENICS is sometimes referred to
individually herein as a “Party”, and
INTERLEUKIN and METAGENICS are sometimes referred to collectively herein as the “Parties”.

 

WHEREAS, INTERLEUKIN is the
owner of, or otherwise controls, genetic testing services currently sold under the PerioPredict® brand name (the
“Test” or “Tests”);
and

 

WHEREAS, METAGENICS
desires to purchase the Tests and accompanying Services;

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending
to be legally bound, hereby agree as follows:

 

 

1.DEFINITIONS

 

Whenever used in this
Agreement with an initial capital letter, the terms defined in this Section 1 shall have the meanings specified.

 

1.1“Affiliate”
means, with respect to any Party, any person that, directly or through one or more Affiliates, controls, or is controlled
by, or is under common control with, such Party. For purposes of this definition, “control” means (a) ownership
of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation,
or more than fifty percent (50%) of the equity interests in the case of any other type of legal entity, (b) status as a general
partner in any partnership, or (c) any other arrangement whereby a person controls or has the right to control the board of directors
of a corporation or equivalent governing body of an entity other than a corporation.

 

1.2“Applicable
Laws” means Federal, state, local, national and supra-national laws, statutes, rules and regulations, including
any rules, regulations, guidance, guidelines or requirements of regulatory authorities, national securities exchanges or securities
listing organizations, that may be in effect from time to time during the Term and applicable to a particular activity hereunder.

 

1.3“Change
of Control” means, with respect to METAGENICS, (a) a merger, consolidation, share exchange or other similar transaction
involving METAGENICS and any third party (a “Third Party”) which results in the holders of the outstanding
voting securities of METAGENICS immediately prior to such merger, consolidation, share exchange or other similar transaction ceasing
to hold more than fifty percent (50%) of the combined voting power of the surviving, purchasing or continuing entity immediately
after such merger, consolidation, share exchange or other similar transaction (or such lesser percentage which is the maximum
allowed to be owned by a foreign corporation in a particular jurisdiction); (b) any transaction or series of related transactions
(other than an investment transaction by an entity not engaged in the pharmaceutical or biotechnology business, the purpose of
which is to raise capital for METAGENICS) in which a Third Party, together with its Affiliates, becomes the beneficial owner of
fifty percent (50%) or more of the combined voting power of the outstanding securities of METAGENICS (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction), or (c) the sale or other transfer
to a Third Party of all or substantially all of METAGENICS’ assets which relate to this Agreement.

 

 

 

	INTERLEUKIN/Agreement	Page
    1

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

  

1.4“Confidential
Information” means (a) with respect to INTERLEUKIN, all tangible embodiments of the Tests; and (b) with respect
to METAGENICS, all data provided to INTERLEUKIN regarding its employees provided to INTERLEUKIN for the purpose of providing the
Tests and the Services; and (c) with respect to each Party, all information and technology disclosed or provided by or on behalf
of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”)
or to any of the Receiving Party’s employees, consultants, Affiliates or sublicensees pursuant to or in connection with
this Agreement; provided, that, none of the foregoing shall be Confidential Information if: (i) as of the date of disclosure by
the Disclosing Party, it is known to the Receiving Party or its Affiliates as demonstrated by contemporaneous written documentation,
other than by virtue of a prior confidential disclosure to such Receiving Party; (ii) as of the date of disclosure by the Disclosing
Party, it is in the public domain, or it subsequently enters the public domain through no fault of the Receiving Party; (iii)
it is obtained by the Receiving Party from a Third Party having a lawful right to make such disclosure free from any obligation
of confidentiality to the Disclosing Party; or (iv) it is independently developed by or for the Receiving Party without reference
to or use of any Confidential Information of the Disclosing Party as demonstrated by contemporaneous written documentation. For
purposes of clarity, the terms of this Agreement shall constitute Confidential Information of each Party.

 

1.5“Control”
or “Controlled” means, with respect to technology, patent rights, trademarks, design looks, or copyrights,
the possession by a Party of the right to grant a license or sublicense to such technology, patent rights, trademarks, design
looks, or copyrights as provided herein without the payment of additional consideration to, and without violating the terms of
any agreement or arrangement with, any Third Party and without violating any Applicable Law.

 

1.6“Effective
Date” means the date first set forth above in the introductory paragraph to this Agreement.

 

1.7“Force
Majeure Event” means any occurrence beyond the reasonable control of a Party that (a) prevents or substantially
interferes with the performance by such Party of any of its obligations hereunder and (b) occurs by reason of any act of God,
flood, fire, explosion, earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion,
act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement
of any government or of any subdivision, authority or representative of any such government.

 

 

 

	INTERLEUKIN/Agreement	Page
    2

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

1.8“Program”
means the combined product offering from INTERLEUKIN, including both the Tests and accompanying Services.

 

1.9“Promotional
and Marketing Materials” means all websites, marketing, sales, promotional or other published literature used in
connection with the Tests.

 

1.10“Sample
Collection Sets” means the materials necessary for INTERLEUKIN to process the Tests.

 

1.11“Services”
means any efforts INTERLEUKIN employs to enable access to, and utilization of, the Tests to employees of METAGENICS, including
but not limited to providing Sample Collection Sets, Promotional and Marketing Materials, and educational webinars to providers.

 

 

2.INTERLEUKIN RESPONSIBILITIES

 

2.1INTERLEUKIN
will provide the Tests and the Services to METAGENICS’ employees.

 

2.2Performance
of a Test. All of the Tests will be processed at INTERLEUKIN’s CLIA certified laboratory in Waltham, MA. INTERLEUKIN
will provide Test results consistent with INTERLEUKIN standard procedures approximately two (2) weeks from the receipt by INTERLEUKIN
of cheek swabs.

 

 

3.METAGENICS RESPONSIBILITIES

 

3.1METAGENICS
will pay INTERLEUKIN the price per Test shown in Exhibit A.

 

3.2METAGENICS
will provide INTERLEUKIN with data required to deliver the Services, including contact information for its employees to whom it
makes the Tests available, and, if available and agreed-upon by both Parties, de-identified dental and medical usage codes for
its employees solely for the purpose of assessing and reporting various metrics regarding the effectiveness of the Services.

 

3.3METAGENICS
will work collaboratively with INTERLEUKIN to enable reasonable access to its employees for communications solely for the purpose
of communicating the benefits, and increasing the effective utilization, of the Program.

 

3.4METAGENICS
will send out email and mail communications to its employees informing them of the Program and methods by which they may access
the Tests.

 

 

 

	INTERLEUKIN/Agreement	Page
    3

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

4.PAYMENT TERMS

 

4.1INTERLEUKIN
shall provide an invoice to METAGENICS for all Tests performed in the previous month, billed at the rate shown in Exhibit A.

 

4.2Payment from
METAGENICS is due in full within thirty (30) days from the date METAGENICS receives the invoice. Invoices that are past due by
more than seven (7) days will be subject to a late charge of one percent (1%) per month on the amount of the past due balance.

 

 

5.COVENANTS, REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION

 

5.1Covenants, Representations and
Warranties. Each Party covenants, represents and warrants to the other Party that:

 

		5.1.1	it
                                         has full power and authority to enter into this Agreement and to perform its obligations
                                         hereunder;

 

		5.1.2	it
                                         will meet its obligations hereunder in a professional and workmanlike manner and with
                                         personnel with appropriate expertise and experience;

 

		5.1.3	it
                                         has obtained all permits, licenses, and other governmental authorizations and approvals
                                         required for its performance under this Agreement;

 

		5.1.4	the
                                         products to be sold and the services to be rendered by each Party and the exercise of
                                         the licenses and rights granted hereunder shall not infringe or violate any patent, copyright,
                                         trademark, or other proprietary right of any Third Party; and

 

		5.1.5	it
                                         will fully comply with all Applicable Laws and regulations.

 

5.2Indemnification
of METAGENICS by INTERLEUKIN. INTERLEUKIN shall indemnify, defend and hold harmless METAGENICS, its Affiliates, their respective
directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, the “METAGENICS
Indemnitees”), against any losses (“Losses”)
incurred by or imposed upon the METAGENICS Indemnitees, or any one of them, as a direct result of claims (“Claims”)
arising out of (a) the material breach by INTERLEUKIN of this Agreement, except with respect to any Claims or Losses that result
from a breach of this Agreement by, or the gross negligence or willful misconduct of, METAGENICS; provided, however, that, with
respect to any Claim for which METAGENICS has an obligation to any INTERLEUKIN Indemnitee pursuant to Section 5.3 and INTERLEUKIN
has an obligation to any METAGENICS Indemnitee pursuant to this Section 5.2, each Party shall indemnify each of the other Party’s
Indemnitees for its Losses to the extent of its responsibility, relative to the other Party, for the facts underlying the Claim.

 

 

 

	INTERLEUKIN/Agreement	Page
    4

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

5.3Indemnification
of INTERLEUKIN by METAGENICS. METAGENICS shall indemnify, defend and hold harmless INTERLEUKIN, its Affiliates, their respective
directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, the “INTERLEUKIN
Indemnitees”), against any Losses incurred by or imposed upon the INTERLEUKIN Indemnitees, or any one of
them, as a direct result of Claims arising out of (a) the material breach by METAGENICS of this Agreement, except with respect
to any Claims or Losses that result from a breach of this Agreement by, or the gross negligence or willful misconduct of, INTERLEUKIN;
provided, however, that, with respect to any Claim for which INTERLEUKIN has an obligation to any METAGENICS Indemnitee pursuant
to Section 5.2 and METAGENICS has an obligation to any INTERLEUKIN Indemnitee pursuant to this Section 5.3, each Party shall indemnify
each of the other Party’s Indemnitees for its Losses to the extent of its responsibility, relative to the other Party, for
the facts underlying the Claim.

 

5.4Conditions
to Indemnification. A person seeking recovery under this Section 5 (the “Indemnified Party”) in
respect of a Claim shall give prompt notice of such Claim to the Party from which recovery is sought (the “Indemnifying
Party”) and, provided that the Indemnifying Party is not contesting its obligation under this Section 5, shall permit
the Indemnifying Party to control any litigation relating to such Claim and the disposition of such Claim; provided that the Indemnifying
Party (a) acts reasonably and in good faith with respect to all matters relating to the settlement or disposition of such Claim
as the settlement or disposition relates to such Indemnified Party and (b) does not settle or otherwise resolve such claim without
the prior written consent of such Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed).
Each Indemnified Party shall cooperate with the Indemnifying Party in its defense of any such Claim in all reasonable respects
and shall have the right to be present in person or through counsel at all legal proceedings with respect to such Claim.

 

 

6.TERM AND TERMINATION

 

6.1Term.
The initial term of this Agreement shall commence on the Effective Date and continue for a period of twelve (12) months (the “Initial
Term”). Thereafter, this Agreement may be renewed for additional terms of twelve (12) months (each, a “Renewal
Term” and together with the Initial Term, the “Term”) and shall be considered automatically
so renewed, unless sooner terminated in accordance with this Section 6.

 

6.2Termination.
Either party shall have the right to terminate this Agreement upon the occurrence of any of the following events:

 

		6.2.1	Confidential
                                         Information. Immediately upon written notice if the other Party breaches confidentiality.

 

		6.2.2	Other
                                         Defaults. If the other Party defaults in the performance of any of its material obligations
                                         under this Agreement and such default continues for a period of fifteen (15) days after
                                         receipt of written notice specifying the nature of the breach.

 

		6.2.3	Without
                                         Cause. For any or no reason, upon at least thirty (30) days’ prior written
                                         notice to the other Party.

 

 

 

	INTERLEUKIN/Agreement	Page
    5

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

6.3Effect of
Termination. Upon termination of this Agreement, all rights and licenses granted under this Agreement shall terminate, provided,
however, that the provisions of Section 2.2, Article 5 and Section 7.8 shall survive termination.

 

 

7.GENERAL

 

7.1Press Releases.
Any press releases regarding the relationship of the Parties under this Agreement must be approved by both Parties before issuance
of such release to the public.

 

7.2Force Majeure.
Neither Party will be liable to the other for any failure to perform any obligation under this Agreement if such failure is caused
by, or arises from, an act of force majeure, including acts of God, war, riot, natural disaster, governmental order or any other
cause beyond the reasonable control of such Party. Under no circumstances shall INTERLEUKIN be excused of its responsibilities
under this Agreement if its delay or failure to perform is a result of a labor dispute or strike.

 

7.3Governing
Law; No Waiver; Attorneys’ Fees; Counterparts. This Agreement shall be governed by and interpreted according to the
laws of the Commonwealth of Massachusetts, without regard to the conflicts of law provisions of Commonwealth of Massachusetts
or any other state or country. Each Party (a) agrees that any litigation arising out of this Agreement may be brought only in
the state or federal courts whose jurisdiction includes Suffolk County, Commonwealth of Massachusetts, (b) consents to the jurisdiction
of such courts, and (c) waives any argument that any such court is an inconvenient forum. No failure or delay by a Party in exercising
any right, power or privilege hereunder will be deemed or operate as a waiver thereof, nor will any single or partial exercise
thereof preclude any other further exercise of any right, power or privilege hereunder. In the event of any dispute or if it becomes
necessary to enforce the provisions of this Agreement, the successful Party shall be entitled to recover reasonable expenses,
including attorneys and other professional fees, in addition to any other available remedies. This Agreement may be executed in
one or more counterparts, each of which will be deemed to be an original of this Agreement and all of which, when taken together,
will be deemed to constitute one and the same instrument.

 

7.4Assignment.
This Agreement shall not be assigned by either Party to any Third Party without the prior written permission of the other Party
hereto. Non-assignment of this Agreement is also applicable during any Change of Control of METAGENICS.

 

7.5Headings
and Severability. The headings in this Agreement are intended to be a convenience only and are not intended to affect interpretation.
Any invalidity in whole or in part shall not affect the validity of any other provision of this Agreement.

 

7.6Modification.
The terms of this Agreement may not be modified, unless such modification is in writing and signed by duly authorized representatives
of each Party.

 

7.7Waiver.
The waiver of any breach of any covenants and conditions of this Agreement shall not hinder or otherwise prevent the subsequent
enforcement of said rights.

 

 

 

	INTERLEUKIN/Agreement	Page
    6

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

7.8Notice.
Any notice under this Agreement shall be in writing and shall, for all purposes, be deemed to have been fully given on the date
personally delivered or received by registered or certified mail, return receipt requested, postage prepaid, and properly addressed
to the respective Parties at the addresses set forth above, or at such other address for either Party as may be specified by such
Party in accordance with this section for such purpose.

 

Contact Information

 

INTERLEUKIN contact:

 

Paul Voegelin

Vice President, Marketing

Interleukin Genetics, Inc.

135 Beaver Street

Waltham, MA 02452

 

METAGENICS contact:

 

Greg Ziff

Director, Global Compensation and Benefits

Metagenics, Inc.

25 Enterprise, Suite 200

Aliso Viejo, CA 92626

 

 

7.9Any communications
to METAGENICS employees regarding the Program must be approved in writing by both Parties designated contact shown in section
7.8.

 

7.10Exclusion
of Certain Damages. NEITHER PARTY SHALL HAVE ANY LIABILITY WITH RESPECT TO ITS OBLIGATIONS UNDER THIS AGREEMENT FOR ANY CONSEQUENTIAL,
EXEMPLARY, SPECIAL, INCIDENTAL OR PUNITIVE DAMAGES EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

7.11Independent
Contractor. The Parties do not intend by this Agreement to create a partnership, principal/agent or joint venture relationship
and nothing in this Agreement shall be construed as creating such a relationship between the Parties. Neither Party nor its agents
or employees are the representatives of the other Party for any purpose except as expressly set forth in this Agreement, and neither
Party has the power or authority as agent, employee or any other capacity to represent, act for, bind or otherwise create or assume
any obligation on behalf of the other Party for any purpose whatsoever.

 

 

 

	INTERLEUKIN/Agreement	Page
    7

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

7.12Entire
Agreement. This Agreement constitutes the entire agreement between METAGENICS and INTERLEUKIN with respect to the sale of
the Tests and accompanying Services and supersedes all earlier agreements and understandings, oral and written, between the Parties
with regard to such sale.

 

IN WITNESS WHEREOF,
METAGENICS and INTERLEUKIN have duly authorized their representatives to make and sign this Agreement as of the Effective Date
written above.

 

 

INTERLEUKIN:

 

INTERLEUKIN GENETICS, INC.

 

 

	By	/s/
    Mark Carbeau	 
	 	 	 
	Mark Carbeau	 
	Chief Executive Officer	 

  

 

 

METAGENICS:

 

METAGENICS, INC.

 

 

	By	 /s/
    Allison K. Musetich	 
	 	 	 
	Allison K. Musetich	 
	Chief Human Resources Officer	 

 

 

 

	INTERLEUKIN/Agreement	Page
    8

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

    	 

    	Exhibit 10.23

    

 

Exhibit A

 

 

	PerioPredict® Test processing	$[***] per test

 

Price includes any promotional or educational materials provided
with the Program.

 

 

 

	INTERLEUKIN/Agreement	Page
    9

Portions of this Exhibit, indicated by
the mark “[***],” were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]